RxDoctor Payments Data

Vesela Tzoneva, MD

Psychiatry · Shreveport, LANPI 1356436794

Payments from drug & device makers

$1,126in general payments, 2019–2025

Across 59 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$299
  • Neurocrine Biosciences, Inc.$257
  • Johnson & Johnson$148
  • Otsuka America Pharmaceutical, Inc.$146
  • Alkermes, Inc.$99
  • Lundbeck LLC$77
  • plus $98 from 4 others

What the payments were for

  • Food & beverage$1,126100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,126 in reported general payments places this provider in the 60th percentile of 474 psychiatry providers in Louisiana.

See all psychiatry providers in Louisiana

Medicare billing

Part B allowed, 2024
$9,168
Medicare patients
54
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate100$357,945
Austedo XrDeutetrabenazine106$300,523
IngrezzaValbenazine Tosylate17$95,971
Abilify MaintenaAripiprazole23$64,229
AristadaAripiprazole Lauroxil16$51,920
RexultiBrexpiprazole22$16,034
Divalproex Sodium148$3,844
Divalproex Sodium ErDivalproex Sodium123$3,419
Memantine Hcl78$3,153
Benztropine Mesylate184$2,897
Quetiapine Fumarate109$2,490
Risperidone164$2,470
Aripiprazole41$2,298
Trazodone Hcl160$2,141
Mirtazapine71$1,804

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$148$357,945100 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$299$300,523106 claims
Neurocrine Biosciences, Inc.Ingrezza$257$95,97117 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$146$80,26445 claims
Alkermes, Inc.Aristada$99$51,92016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 474 psychiatry providers in Louisiana.

Other psychiatry in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →